Biocatalytic optimisation of lead compounds by late stage functionalisation
Biocatalytic optimisation of lead compounds by late stage functionalisation is becoming more widely applied within pharma companies to rapidly access and explore compounds that may possess superior properties compared to the original drug candidate. In our scientific newsletter for Q2 we feature case studies where biocatalytic hydroxylation of drugs yielded superior drug candidates compared to the original lead compound, including increased potency, improved metabolic stability and higher polarity. Read more in our newsletter here.
Hypha also recently presented a poster at the RSC MedChem conference on a project with a large pharma company on expanding chemical space via microbial late stage functionalisation. This follows other client projects in which Hypha have generated polar derivatives with improved LLE or other properties. If you are interested in a copy of the poster, please contact us.